当前位置: 首页 >> 检索结果
1. Global, regional, and national burden of inflammatory bowel disease in persons aged 60-89 years from 1992 to 2021.
作者: Zhou Zhang.;Na Du.;Chun-Mei Xu.;Wei Chen.; Ting-Ting-Chen.;Yu Xiao.
来源: BMC Gastroenterol. 2025年25卷1期425页
The global burden of inflammatory bowel disease (IBD) is increasing, but detailed data on older adults remain scarce.
2. Trends in incidence and mortality of early-onset gastrointestinal cancers: a comprehensive study.
Early-Onset Gastrointestinal Cancers concerns tumors in people under 50. Accumulating evidence suggests a significant increase in the burden of colorectal cancer in young adults. We investigated the global burden and spatiotemporal trends of the 6 major gastrointestinal (GI) cancers, including colon and rectum cancer (CRC), esophageal cancer (EC), gallbladder and biliary tract cancer (GBTC), liver cancer (LC), pancreatic cancer (PC), and stomach cancer (SC). in young adults, based on cancer-specific incidence and mortality.
3. Development and validation of a nomogram for predicting early recurrence in patients undergoing different courses of postoperative adjuvant transarterial chemoembolisation.
作者: Hongkun Tan.;Yuyan Xu.;Cheng Zhang.;Kaihang Zhong.;Yaohong Wen.;Chunming Wang.;Zhoubin Feng.;Jianan Feng.;Shunjun Fu.;Guolin He.;Lei Cai.;Mingxin Pan.
来源: BMC Gastroenterol. 2025年25卷1期422页
Hepatocellular carcinoma (HCC) is associated with a high rate of postoperative recurrence. Postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) is effective in preventing recurrence. However, the effect of different courses of PA-TACE on tumor prognosis remains unclear. As such, this study aimed to develop and validate a nomogram that incorporates different courses of PA-TACE to predict early tumor recurrence.
4. Status of short videos as health information sources for chronic pancreatitis in China: a cross-sectional study.
Chronic pancreatitis is a chronic inflammatory disease of the pancreatic tissue caused by genetic or environmental factors; it has a complex etiology and is difficult to diagnose and treat clinically, severely affecting the physical and mental health of patients. Currently, the treatment of chronic pancreatitis often relies on lifelong self-health management by patients. However, the quality of videos related to chronic pancreatitis on short video platforms remains to be determined, and these videos may contain erroneous information that patients cannot recognize. This study aims to assess the quality of information in short videos related to chronic pancreatitis on the Chinese platforms TikTok and Bilibili.
10. Cholesterol-modified prognostic nutritional index as an independent prognostic biomarker in primary biliary cholangitis patients.
作者: Huiling Zhu.;Mengyao Zheng.;Wenbin Li.;Yaqin Huang.;Lili Zhang.;Wenting Yang.;Jinhui Yang.
来源: BMC Gastroenterol. 2025年25卷1期421页
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by inflammation of the interlobular bile ducts, often associated with malabsorption of fat-soluble vitamins and osteoporosis. Thus, evaluating the nutritional status of patients with PBC and implementing appropriate interventions are significant. But CPNI in determining the nutritional status and forecasting survival outcome among patients with PBC remains unclear.
11. Effectiveness of an app-based walking program for obese patients with inflammatory bowel disease in Korea: a single-blind parallel-group randomized clinical trial.
作者: Young Jin Lee.;Eun Ja Kwon.;Da-In Park.;Sang Hyoung Park.;Sung Wook Hwang.;Byong Duk Ye.
来源: BMC Gastroenterol. 2025年25卷1期417页
Obesity in patients with inflammatory bowel disease (IBD) not only exacerbates symptoms but also interferes with treatment and leads to additional complications. Therefore, managing weight loss and preventing obesity are crucial. This study was designed to develop and implement a 10-week walking exercise program, facilitated by a mobile application, to evaluate its effectiveness in managing weight in obese IBD patients.
12. Helicobacter pylori is associated with less tumor-infiltrating lymphocytes and a poor prognosis in gastric cancer.
作者: Zetian Chen.;Zhijun Zhang.;Hongxin Huang.;Chen Lu.;Qingya Li.;Mengpei Yan.;Chengjun Zhu.;Sen Wang.;Hongda Liu.;Zekuan Xu.;Zheng Li.
来源: BMC Gastroenterol. 2025年25卷1期420页
Helicobacter pylori (H. pylori) is carcinogenic and has the potential to cause progressive gastric lesions and gastric cancer (GC), which also represents one of the essential constituents of the tumor microenvironment (TME) of GC. The infiltration and functional status of tumor-infiltrating lymphocytes (TILs) in the TME affect the anti-tumor function of the body. However, the impact of H. pylori on anti-tumor immunity and prognosis of GC is still unclear.
13. Association between the dietary index of gut microbiota and abnormal bowel symptoms in U.S. adults: a cross-sectional study based on NHANES 2007-2010.
作者: Sicheng Shen.;Huayi Feng.;Chuyue Wang.;Yingqi Yang.;Zhiyang Chen.;Xiaopeng Wang.;Jiacheng Li.
来源: BMC Gastroenterol. 2025年25卷1期419页
The Dietary Index of Gut Microbiota (DI-GM) is a newly developed measure for assessing diet quality in relation to the diversity of the gut microbiome. However, whether it is associated with the risk of chronic constipation and chronic diarrhea remains unclear.
14. A novel inflammatory biomarker in assessing disease activity in ulcerative colitis: gasdermin D.
作者: Osman Cagin Buldukoglu.;Serkan Ocal.;Serdar Akca.;Galip Egemen Atar.;Besir Kaya.;Muhammet Devran Isik.;Ozlem Koca.;Ferda Akbay Harmandar.;Yesim Cekin.;Ayhan Hilmi Cekin.
来源: BMC Gastroenterol. 2025年25卷1期418页
Ulcerative colitis (UC) is a chronic inflammatory disease with a worldwide prevalance of around 5 million patients. Assessment of disease activity is crucial in management of UC patients. Gasdermin D (GSDMD) is a protein which belongs to the gasdermin protein family and plays a role in inflammatory cell death, pyroptosis. GSDMD activation has been shown to be related to inflammatory states in a variety of disorders, including inflammatory bowel diseases. With this study, we aimed to reveal a potential new inflammatory serum marker for assessing disease activity and severity in UC patients in a non-invasive manner.
15. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
作者: Jurij Hanžel.;Virginia Solitano.;Sudheer Kumar Vuyyuru.;Remo Panaccione.;Bruce E Sands.;Laurent Peyrin-Biroulet.;Silvio Danese.;Geert R D'Haens.;Raja Atreya.;Matthieu Allez.;Charles N Bernstein.;Peter Bossuyt.;Brian Bressler.;Robert V Bryant.;Benjamin L Cohen.;Jean-Frederic Colombel.;Ferdinando D'Amico.;Axel Dignass.;Marla Dubinsky.;Phillip Fleshner.;Richard B Gearry.;Stephen B Hanauer.;Ailsa L Hart.;Maia Kayal.;Torsten Kucharzik.;Peter L Lakatos.;Edouard Louis.;Fernando Magro.;Neeraj Narula.;Rupert W Leong.;Julián Panés.;Tim Raine.;Zhihua Ran.;Miguel D Regueiro.;Walter Reinisch.;Siddharth Singh.;A Hillary Steinhart.;Simon Travis.;Ryan C Ungaro.;C Janneke van der Woude.;Takayuki Yamamoto.;Vineet Ahuja.;David T Rubin.;Parambir S Dulai.;Linda J Cornfield.;Malcolm Hogan.;William J Sandborn.;Brian G Feagan.;Vipul Jairath.;Christopher Ma.
来源: Gastroenterology. 2025年
Approval of new therapies for inflammatory bowel disease (IBD) requires rigorously designed and well-executed randomized controlled trials (RCTs). Corticosteroids remain a cornerstone of IBD induction therapy and many patients in trials are enrolled while taking corticosteroids. Despite this, approaches to corticosteroid management in RCTs have been highly heterogeneous, often differing from clinical practice. This negatively impacts patients' willingness to participate due to prolonged corticosteroid exposure and may potentially bias outcomes in the clinical trial. Our aim is to provide comprehensive standardized recommendations on key aspects of corticosteroid use in IBD clinical trials through a multi-phase, international expert consensus, with a goal to help inform and standardize practice in future RCTs.
16. AAV-mediated silencing of Sox4 leads to long-term amelioration of liver phenotypes in mouse models of Alagille syndrome.
作者: Duncan Fox.;Jun Xie.;Jennifer L Burwinkel.;Josh M Adams.;Kashish Chetal.;Marzieh Keivandarian.;Yaniv Faingelernt.;Sanjay Subramanian.;Mario F Lopez.;Anna L Peters.;Nathan Salomonis.;Neda Zarrin-Khameh.;Guangping Gao.;Stacey S Huppert.;Hamed Jafar-Nejad.
来源: Gastroenterology. 2025年
In patients with Alagille syndrome (ALGS), bile duct paucity often leads to severe cholestatic phenotypes for which liver transplantation remains the only definitive treatment. No FDA-approved mechanism-based strategies exist to enhance biliary development in ALGS or other diseases with bile duct paucity. We aimed to identify a therapeutic target to address this unmet need.
20. Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.
作者: Ye Zhang.;Jie Chen.;Fenglian Yu.;Wenxiong Zhang.;Yingmei Zhong.
来源: BMC Gastroenterol. 2025年25卷1期416页
Neoadjuvant chemotherapy (NC) is a cornerstone in the management of resectable esophageal squamous cell carcinoma (ESCC). The integration of PD-1/PD-L1 inhibitors into NC (NIC) regimens has shown promise; however, its efficacy and safety remain uncertain. This meta-analysis aims to compare the potential risks and clinical benefits of NIC versus NC in patients with resectable ESCC based on randomized controlled trials (RCTs).
|